Details
Stereochemistry | RACEMIC |
Molecular Formula | C11H16N2O3.ClH |
Molecular Weight | 260.717 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CC(C)NCC(O)C1=CC=C(C=C1)[N+]([O-])=O
InChI
InChIKey=STGOXRVTUNXXLQ-UHFFFAOYSA-N
InChI=1S/C11H16N2O3.ClH/c1-8(2)12-7-11(14)9-3-5-10(6-4-9)13(15)16;/h3-6,8,11-12,14H,7H2,1-2H3;1H
Nifenalol is the beta-receptor antagonist. It has optical isomers. The racemic mixture and the levo-isomer are active in antagonizing beta-receptors, but the dextro-isomer is inactive. The levo-isomer seems to be about twice as active in blocking beta-receptors as the racemate. Nifenalol is virtually devoid of local anesthetic properties in contrast to procaine, propranolol, and butidrine. Nifenalol exacerbated the fighting behavior in male mice by foot-shock. Nifenalol has been studied in patients with coronary artery disease. It afforded the coronary patient good protection against angina and ischemic changes in the EKG. It was further noted that nifenalol had no antiarrhythmic action and that it was devoid of evident side effects. Nifenalol possessed weak action against tremorine and oxotremorine induced tremor.
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
Blockade of epinephrine- and ouabain-induced cardiac arrhythmias in the dog heart-lung preparation. | 1966 May |
|
Tremorine-oxotremorine-induced tremor, hypothermia and analgesia, and physostigmine toxicity, in mice after pretreatment with beta-adrenoceptor antagonists. | 1976 Apr |
|
Cardiac action of carazolol and methypranol in comparison with other beta-receptor blockers. | 1977 |
|
[Influence of the beta-receptor blocker nifenalol on insulin secretion in normal subjects and diabetic patients (author's transl)]. | 1977 Feb |
|
Differentiation of beta-adrenoceptors in right atrium, diaphragm and adipose tissue of the rat, using stereoisomers of propranolol, alprenolol, nifenalol and practolol. | 1977 Jul 1 |
|
Effect of (+) INPEA, (+) sotalol and deoxysotalol on the in vitro production of prostaglandins E and F by the rat uterus. | 1980 Apr |
|
Effects of 1-(4-nitrophenyl)-2-isopropylaminoethanol (INPEA) and propranolol and their dextro-isomers on hemodynamic and metabolic responses to isoproterenol in dogs. | 1983 Aug |
|
[Iatrogenic dermatoses caused by beta-blocking drugs]. | 1983 Nov-Dec |
|
Effects of bucumolol, nadolol and nifenalol on maximum upstroke velocity of action potential in guinea pig papillary muscles. | 1986 Mar |
|
Resveratrol activity on guinea pig isolated trachea from normal and albumin-sensitized animals. | 1988 Dec |
|
Arrhythmogenic effect of beta-adrenoceptor-blocking drugs in Purkinje fibres of guinea-pig hearts. | 1996 Jan-Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6688273
Dog: 5 or 15 mg/kg
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2872598
The effects of nifenalol (NIF) on contractile forces and on action potentials (APs) were investigated in isolated guinea pig atrial and papillary muscles, respectively. Log 1/ED40 values for the negative inotropic effects of this drug was 0.74 mmol/l in this order. NIF (0.2 mmol/l) produced about 20% reduction of Vmax at 1 Hz.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2KMT7J8EZC
Created by
admin on Fri Dec 15 18:35:27 GMT 2023 , Edited by admin on Fri Dec 15 18:35:27 GMT 2023
|
PRIMARY | |||
|
100000085718
Created by
admin on Fri Dec 15 18:35:27 GMT 2023 , Edited by admin on Fri Dec 15 18:35:27 GMT 2023
|
PRIMARY | |||
|
DTXSID90972520
Created by
admin on Fri Dec 15 18:35:27 GMT 2023 , Edited by admin on Fri Dec 15 18:35:27 GMT 2023
|
PRIMARY | |||
|
5704-60-9
Created by
admin on Fri Dec 15 18:35:27 GMT 2023 , Edited by admin on Fri Dec 15 18:35:27 GMT 2023
|
PRIMARY | |||
|
SUB03433MIG
Created by
admin on Fri Dec 15 18:35:27 GMT 2023 , Edited by admin on Fri Dec 15 18:35:27 GMT 2023
|
PRIMARY | |||
|
m1218
Created by
admin on Fri Dec 15 18:35:27 GMT 2023 , Edited by admin on Fri Dec 15 18:35:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
227-194-1
Created by
admin on Fri Dec 15 18:35:27 GMT 2023 , Edited by admin on Fri Dec 15 18:35:27 GMT 2023
|
PRIMARY | |||
|
6316
Created by
admin on Fri Dec 15 18:35:27 GMT 2023 , Edited by admin on Fri Dec 15 18:35:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD